Asia Pac Allergy.  2013 Apr;3(2):79-87. 10.5415/apallergy.2013.3.2.79.

Overview of atopic dermatitis

• Kim KH

• KMID: 2400402
• DOI: http://doi.org/10.5415/apallergy.2013.3.2.79

Abstract

Atopic dermatitis (AD) is a very common chronic disease that reportedly affects 10%-20% of the general population. The prevalence of AD appears to be steadily increasing, at least in developing countries. Two pathogenetic mechanisms have been mentioned. Traditionally immunological aberrations are thought to be a primary event in the initial development of AD ("inside-to-outside hypothesis"). Another hypothesis assumes that there is an intrinsic defect in epidermal barrier. Due to this barrier defect, allergens or irritants can easily penetrate the epidermal barrier, and induce immunologic reaction secondarily ("outside-to-inside hypothesis"). These days the epidermal barrier defect seems to gain more support as a primary event than immunological aberrations in the early changes of AD since the filaggrin mutation was reported in AD patients. Clinically AD initially affects face, and with age, flexural areas are typically involved. AD has many different clinical features. Diagnostic criteria for AD in each country may be a little different, although based on the criteria proposed by Hanifin and Rajka. AD can be controlled effectively with topical and/or systemic treatments and fortunately spontaneously disappears with age. However, in some cases very resistant to conventional therapies, additional treatments such as immunosuppressive agents are needed.

Keyword

Atopic dermatitis; Prevalence; Immunological aberrations; Epidermal barrier defect; Filaggrin mutation

MeSH Terms

Allergens
Chronic Disease
Dermatitis, Atopic*
Developing Countries
Humans
Immunosuppressive Agents
Irritants
Prevalence
Allergens
Immunosuppressive Agents
Irritants

Figure

• 

  Fig. 1 Two pathogenetic mechanisms. Which one is first, immunological aberrations (inside-to-outside hypothesis) or epidermal barrier defect (outside-to-inside hypothesis)? These days more emphasis is given to barrier defect in the early changes in the evolution of AD ever since FLG mutation was reported. FLG, filaggrin; Epid, epidermis; TEWL, transepidermal water loss; AD, atopic dermatitis.

• 

  Fig. 2 Perioral area typically affected first due to irritation of saliva.

• 

  Fig. 3 Flexural areas are typically affected in patients over 2 yr.

• 

  Fig. 4 Periauricular eczematization.

Reference

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980. 59:44–47.

2. Bieber T. Atopic dermatitis. N Engl J Med. 2008. 358:1483–1494.

3. Choi WJ, Ko JY, Kim JW, Lee KH, Park CW, Kim KH, Kim MN, Lee AY, Cho SH, Park YL, Choi JH, Seo SJ, Lee YW, Roh JY, Park YM, Kim DJ, Ro YS. Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children. Acta Derm Venereol. 2012. 92:467–471.

4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006. 38:441–446.

5. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009. 129:1892–1908.

6. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, Mitchell EA, Pearce N, Sibbald B, Stewart AW, Strachan D, Weiland SK, Williams HC. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995. 8:483–491.

7. Asher MI, Weiland SK. The International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Steering Committee. Clin Exp Allergy. 1998. 28:Suppl 5. 52–66.

8. Maziak W, Behrens T, Brasky TM, Duhme H, Rzehak P, Weiland SK, Keil U. Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Munster, Germany. Allergy. 2003. 58:572–579.

9. Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, Stricker T, Eigenmann PA, Braun-Fahrlander C. Swiss Surveillance Programme on Childhood Allergy and Respiratory symptoms with respect to Air Pollution (SCARPOL) team. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006. 61:556–562.

10. Selnes A, Nystad W, Bolle R, Lund E. Diverging prevalence trends of atopic disorders in Norwegian children. Results from three cross-sectional studies. Allergy. 2005. 60:894–899.

11. Olesen AB, Bang K, Juul S, Thestrup-Pedersen K. Stable incidence of atopic dermatitis among children in Denmark during the 1990s. Acta Derm Venereol. 2005. 85:244–247.

12. Yura A, Shimizu T. Trends in the prevalence of atopic dermatitis in school children: longitudinal study in Osaka Prefecture, Japan, from 1985 to 1997. Br J Dermatol. 2001. 145:966–973.

13. Oh JW, Pyun BY, Choung JT, Ahn KM, Kim CH, Song SW, Son JA, Lee SY, Lee SI. Epidemiological change of atopic dermatitis and food allergy in school-aged children in Korea between 1995 and 2000. J Korean Med Sci. 2004. 19:716–723.

14. Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Prevalence of atopic dermatitis in Japanese adults. Br J Dermatol. 2003. 148:117–121.

15. Saeki H, Iizuka H, Mori Y, Akasaka T, Takagi H, Kitajima Y, Tezuka T, Tanaka T, Hide M, Yamamoto S, Hirose Y, Kodama H, Urabe K, Furue M, Kasagi F, Torii H, Nakamura K, Morita E, Tsunemi Y, Tamaki K. Prevalence of atopic dermatitis in Japanese elementary schoolchildren. Br J Dermatol. 2005. 152:110–114.

16. Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 2009. 129:1878–1891.

17. Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008. 27:128–137.

18. Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012. 122:440–447.

19. Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, Ota M, Sugiura H, Yamamoto K, Sato H, Palmer CN, Smith FJ, McLean WH, Shimizu H. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007. 119:434–440.

20. Hsu CK, Akiyama M, Nemoto-Hasebe I, Nomura T, Sandilands A, Chao SC, Lee JY, Sheu HM, McLean WH, Shimizu H. Analysis of Taiwanese ichthyosis vulgaris families further demonstrates differences in FLG mutations between European and Asian populations. Br J Dermatol. 2009. 161:448–451.

21. Kang TW, Lee JS, Oh SW, Kim SC. Filaggrin mutation c.3321delA in a Korean patient with ichthyosis vulgaris and atopic dermatitis. Dermatology. 2009. 218:186–187.

22. Seo S, Park M, Jeong M, Kim J, Kim I, Li K. Clinical characteristics correlates with impaired barrier in filaggrin gene related Korean atopic dermatitis patients [abstract]. J Invest Dermatol. 2012. 132:S91.

23. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol. 1995. 75:429–433.

24. Anderson PC, Dinulos JG. Are the new moisturizers more effective? Curr Opin Pediatr. 2009. 21:486–490.

25. Bunikowski R, Mielke M, Skarabis H, Herz U, Bergmann RL, Wahn U, Renz H. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol. 1999. 103:119–124.

26. Schmid-Grendelmeier P, Flückiger S, Disch R, Trautmann A, Wüthrich B, Blaser K, Scheynius A, Crameri R. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol. 2005. 115:1068–1075.

27. Park YL, Kim HD, Kim KH, Kim MN, Kim JW, Ro YS, Park CW, Lee KH, Lee AY, Cho SH, Choi JH. Report from ADRG: a study on the diagnostic criteria of Korean atopic dermatitis. Korean J Dermatol. 2006. 44:659–663.

28. Mevorah B, Frenk E, Wietlisbach V, Carrel CF. Minor clinical features of atopic dermatitis. Evaluation of their diagnostic significance. Dermatologica. 1988. 177:360–364.

29. Kanwar AJ, Dhar S, Kaur S. Evaluation of minor clinical features of atopic dermatitis. Pediatr Dermatol. 1991. 8:114–116.

30. Nagaraja , Kanwar AJ, Dhar S, Singh S. Frequency and significance of minor clinical features in various age-related subgroups of atopic dermatitis in children. Pediatr Dermatol. 1996. 13:10–13.

31. Lee HJ, Cho SH, Ha SJ, Ahn WK, Park YM, Byun DG, Kim JW. Minor cutaneous features of atopic dermatitis in South Korea. Int J Dermatol. 2000. 39:337–342.

32. Kim KH, Hwang JH, Park KC. Periauricular eczematization in childhood atopic dermatitis. Pediatr Dermatol. 1996. 13:278–280.

33. Hayashida S, Furusho N, Uchi H, Miyazaki S, Eiraku K, Gondo C, Tsuji G, Hachisuka J, Fukagawa S, Kido M, Nakahara T, Moroi Y, Hayashi J, Hagihara A, Furue M. Are lifetime prevalence of impetigo, molluscum and herpes infection really increased in children having atopic dermatitis? J Dermatol Sci. 2010. 60:173–178.

34. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002. 347:1151–1160.

35. Hata TR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg. 2008. 27:144–150.

36. Kim KH, Park KC. Clinical characteristics of adult atopic dermatitis. Ann Dermatol. 1998. 10:229–232.

37. Seidenari S, Giusti F. Intrinsic vs. extrinsic atopic dermatitis: a study on diagnostic definition and prevalence [abstract]. J Invest Dermatol. 2003. 121:1255.

38. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010. 58:1–7.

39. Krakowski AC, Dohil MA. Topical therapy in pediatric atopic dermatitis. Semin Cutan Med Surg. 2008. 27:161–167.

40. Borchard KL, Orchard D. Systemic therapy of paediatric atopic dermatitis: an update. Australas J Dermatol. 2008. 49:123–136.

41. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol. 2007. 87:100–111.

42. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza AM, Giusti F, Lubbe J, Seidenari S, Ring J. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010. 24:317–328.

43. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, Sasaki R, Suto H, Takehara K. Committee for Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association. Guidelines for management of atopic dermatitis. J Dermatol. 2009. 36:563–577.

44. Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M. European Tacrolimus Ointment Study Group. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008. 63:742–750.

45. Thaçi D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010. 28:52–56.

46. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol. 2000. 25:552–558.

47. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007. 32:28–33.

48. Hijnen DJ, ten Berge O, Timmer-de Mik L, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 2007. 21:85–89.

49. Kim SW, Park YW, Kwon IH, Kim KH. Cyclosporin treatment of atopic dermatitis: is it really associated with infectious diseases? Ann Dermatol. 2010. 22:170–172.

50. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007. 157:127–132.

51. Kwon HH, Kim KH. Intravenous immunoglobulin treatment in a child with resistant atopic dermatitis. Ann Dermatol. 2012. 24:66–69.

52. Oh J, Kim J, Baik H, Lee H. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe atopic dermatitis in childhood. J Allergy Clin Immunol. 2011. 127:Ab36.

53. Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010. 24:43–49.

54. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, Hotchkiss K, Graham-Brown RA. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002. 147:324–330.

55. Cadario G, Galluccio AG, Pezza M, Appino A, Milani M, Pecora S, Mastrandrea F. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007. 23:2503–2506.

56. Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012. 12:427–433.

57. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. 2008. 121:116–121.e11.

58. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005. 60:494–500.